Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors

202257 citationsJournal Articlehybrid Open Access

Authors

Xavier Boumaza · Université Fédérale de Toulouse Midi-Pyrénées

Baptiste Bonneau · Université Fédérale de Toulouse Midi-Pyrénées

Damien Roos‐Weil · Sorbonne Université

Carmela Pinnetti · Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Sebastian Rauer · University of Freiburg

Louisa Nitsch · University Hospital Bonn

Arnaud Del Bello

Abstract

In this noncontrolled retrospective study of patients with PML who were treated with immune checkpoint inhibitors, mortality remains high. Development of inflammatory features or overt PML-IRIS was commonly observed. This study highlights that use of immune checkpoint inhibitors should be strictly personalized toward characteristics of the individual PML patient. ANN NEUROL 2023;93:257-270.

Topics & Keywords

Polyomavirus and related diseases Cooperative Communication and Network Coding Full-Duplex Wireless Communications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Neurology

Volume 93, Issue 2, pp. 257-270

DOI: 10.1002/ana.26512

Field-Weighted Citation Impact: 5.34